Current Research Activities

Current Projects

  • Estimating Human Health Risks from Developmental Exposure to Nanomaterials
  • Linking Exposure and Tissue Response Models Using Physiologically Based Pharmacokinetic Modeling Approaches
  • Evaluation of In Vitro to In Vivo Extrapolation Approach for Toxicity Assessment
  • Reverse Dosimetry Exposure Modeling for Interpreting In Vitro Assay Results from the U.S. EPA’s TOXCAST program
  • Interpretation of Biomonitoring Data for Ortho-Phthalates Using PBPK Modeling: Estimation of Fetal Exposure and Risks
  • Development of a PBPK Models for Interpreting Biomonitoring Data on Carbaryl and other N-methyl-Carbamates
  • Development of PBPK Models to Evaluate Human Exposures to Perfluorinated Compound
  • Investigation of Genomic Dose Response Relevant to a Human Health Risk Assessment for Arsenic
  • Risk Assessment for Chloroprene
  • Development of PBPK models for Manganese and their Application in Risk Assessment
  • PBPK Modeling of Novel Drug Delivery
  • Developing a Computational Model for Predicting Drug Induced Liver Injury (DILI)

Previously Held Courses

  • Physiologically Based Pharmacokinetic  Modeling and In Vitro to In Vivo Extrapolation Workshop, April 2010
  • Physiologically Based Pharmacokinetic Modeling in Drug Development and Evaluation Workshop, April 2009
  • Physiologically-Based Pharmacokinetic Modeling and Risk Assessment Workshop, February 2008.
  • A Course on Interpretation of Biomonitoring Data Using Physiologically Based Pharmacokinetic Modeling, September 2006.
  • Physiologically Based Pharmacokinetic Modeling and Risk Assessment Workshop, September 2005 and February 2006.